Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LY03010 vs Invega Sustenna in Schizophrenia
NCT03751488Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paliperidone in schizophrenia and schizoaffective disorder (4 arms), sponsored by Luye Pharma Group. Primary endpoints: Area Under the Curve at 120 days, Maximum Plasma Concentration at 120 days and 1 more. Started Dec 2018; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT03751488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751488.